BRAXF News and Press, Braxia Scientific Corp From 05/20/22

Braxia Scientific (OTCPK:BRAXF) said on Friday that Canada had approved its application to the Special Access Program (SAP) to provide psilocybin-assisted psychotherapy for a patient with Major Depressive Disorder in Ontario. This is the company's first psilocybin-assisted therapy t...

Braxia Scientific Receives Health Canada Special Access Program Approval to Provide Psilocybin-Assisted Therapy for Depression in Ontario Canada NewsWire Health Canada approval is for a patient with the indication of Major Depressive Disorder, in the absence of ter...

Braxia Scientific to Present at H.C. Wainwright Global Investment Conference, Miami from May 24-26, 2022 Canada NewsWire TORONTO , May 19, 2022 /CNW/ - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical r...

Braxia Scientific CEO to Speak at American Psychiatric Association Annual Meeting on Treatment Resistant Depression and Ketamine Guidelines Published in American Journal of Psychiatry Canada NewsWire TORONTO , May 18, 2022 /CNW/ - Braxia Scientific Corp. ...

Braxia Scientific CEO and CMO, Invited to Speak as Experts at the Ketamine and Related Compounds 2022 International Conference hosted by University of Oxford April 4-6 Canada NewsWire TORONTO , April 1, 2022 /CNW/ - Braxia Scientific Corp. ("Braxia Scient...

Braxia Scientific Reports Q3 2022 Financial Results; Company Leads in Psychedelic Research, Access and Therapist Training with First Multi-Dose Psilocybin Trial in Canada Canada NewsWire Achieved milestone with the start of landmark psilocybin clinical trial in Q3 2021...

Braxia Scientific Provides Update on Large Proprietary Dataset Expected to Support Pharmaceutical and Industry Clinical Trials for Ketamine and Psilocybin Drug Development Canada NewsWire TORONTO , Jan. 31, 2022 /CNW/ - Braxia Scientific Corp. ("Braxia", or the "...

Braxia Scientific Achieves Milestone as Landmark Psilocybin Clinical Trial Commences, Participants Receive First Doses of Psilocybin Canada NewsWire Patients receive first dose in first-ever Health Canada-approved, multi-dose psilocybin clinical trial conducted at Brax...

Braxia Scientific (OTCPK:BRAXF): FQ2 Net loss for the quarter decreased 16% Y/Y  to $1.71M. Revenue of C$0.39M (+56.0% Y/Y) Press Release The Company's cash and cash equivalents as of September 30, 2021, was C$9.61M compared with C$10.26M at June 30, 2021. For further details see: ...

Braxia Scientific CEO Dr. Roger McIntyre to Join Advisory Board of At-Home Telemedicine Platform KetaMD Canada NewsWire TORONTO , Nov. 9, 2021 /CNW/ - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical re...